

PATENT  
Case: OC01000KQ US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

RYBAK ET AL.

For:

MELANOMA THERAPY

Serial No.: 09/904,263

Filed: July 12, 2001

Examiner: A. HOLLERAN

Group Art Unit: 1642

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**DECLARATION UNDER 37 C.F.R. §1.132 OF CRAIG TENDLER, M.D.**

I, Dr. Craig Tandler, declare and state as follows:

1. I earned a B.A. degree in Biological Sciences from Cornell University in 1980 and an M.D. degree from Mount Sinai School of Medicine in 1984. I was a pediatric intern and resident at Mount Sinai Hospital (New York, NY) from 1984-1988. I was a fellow at the National Cancer Institute, NIH from 1988-1991 and at Mount Sinai Hospital from 1991-1992. I was an assistant professor of pediatrics and pediatric oncology at Mount Sinai School of Medicine from 1992-1995. I am certified in Pediatrics (1988), Advanced Cardiac Life Support (1988) and Pediatric Hematology/Oncology (1992). Attached is a copy of my *curriculum vitae* (Exhibit A).

2. Since 1995, I have been at Schering-Plough Corporation, the assignee of the present patent application. I am currently Vice President, Oncology Clinical Research and Chair, Oncology Licensing Committee. At Schering-Plough, I have supervised clinical trials using INTRON A (interferon alpha 2b) and PEG-INTRON (a pegylated Interferon alpha 2b) to treat high-risk malignant melanoma for the past eight years. I supervised the pivotal trials leading to approval of INTRON A for melanoma treatment by the Food and Drug Administration and other national health authorities.

DO NOT  
ENTER  
ALH  
11/24/2004